BMS-986179 / BMS - LARVOL DELTA

IFN-γ Induces Distinct Single Cell Transcriptomes in Clinical-Grade Mesenchymal Stromal Cells (ASH 2017) - P=N/A; "Single cell RNA-seq analysis of clinical grade BMSCs revealed a significant heterogeneous population composed of multiple clusters with distinct gene expression patterns. IFN-γ further modified the landscape of transcriptomes of BMSC at a single cell level. This transcriptome diversity may explain the differences in the quality of BMSC products for clinical application."

Biosimilar • Graft versus Host Disease • Hematological Malignancies

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - P1/2 | N=234 | Completed | Sponsor: Bristol-Myers Squibb | Active, not recruiting ➔ Completed | Trial completion date: Feb 2023 ➔ Oct 2021 | Trial primary completion date: Feb 2023 ➔ Oct 2021

Combination therapy • Trial completion • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Preliminary phase 1 profile of BMS-986179, an anti-CD73 antibody, in combination with nivolumab in patients with advanced solid tumors (AACR 2018) - P1/2; "BMS-986179 + NIVO was well tolerated, with CD73 target engagement in the tumor and periphery and a safety profile similar to that of NIVO monotherapy. The combination demonstrated preliminary antitumor activity. These data support the ongoing evaluation of this combination in pts with advanced solid tumors."

Clinical • Combination therapy • IO biomarker • P1 data • PD(L)-1 Biomarker • Renal Cell Carcinoma

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - P1/2; N=268; Active, not recruiting; Sponsor: Bristol-Myers Squibb; Recruiting ➔ Active, not recruiting; Trial completion date: Sep 2022 ➔ Feb 2023; Trial primary completion date: Nov 2020 ➔ Feb 2023

Clinical • Combination therapy • Enrollment closed • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Long-Term Engraftment of Primary Bone Marrow Stromal Cells Repairs Niche Damage and Improves Hematopoietic Stem Cell Transplantation. (PubMed, Cell Stem Cell) - "BMSC co-transplantation doubles the number of functional, donor-derived HSCs and significantly reduces clinically relevant side effects associated with HSC transplantation including neutropenia and humoral immunodeficiency. These data demonstrate the potential of stroma recovery to improve HSC transplantation."

Journal • Biosimilar • Hematological Malignancies • Oncology

Acute Myeloid Leukaemia Induces p16 Driven Senescence in the Bone Marrow Microenvironment to Support Their Proliferation and Survival (ASH 2017) - "...2014 Cell Development), in which the herpes simplex virus thymidine kinase (HSV-TK) moiety of the p16-3MR transgene allows selective killing of senescent p16-expressing cells by the pro-drug ganciclovir (GCV)...Here we show that the AML blast induces a senescent phenotype in the bone marrow microenvironment which then feeds back to enhance the growth capacity of the AML blast. Targeting the senescent microenvironment may provide a novel therapeutic approach for the treatment of this disease."

Acute Myelogenous Leukemia • Biosimilar • Hematological Malignancies • Leukemia • Oncology

In vitro characterization of bone marrow stromal cells from osteoarthritic donors. (PubMed, Stem Cell Res) - "However, increased SOX9 and CD90 as well as reduced CD166 expression levels in OA-BMSCs warrant further investigation. These data will help to further understand the role of BMSC in OA and facilitate the application of autologous cell-based strategies for musculoskeletal tissue regeneration in OA patients."

Journal • Biosimilar • CNS Disorders • Immunology • Inflammation • Osteoarthritis • Pain

Transcriptome Alterations of Prospectively Isolated Bone Marrow Stromal Cells Provide Potential Cues to MGUS and Multiple Myeloma Pathobiology (ASH 2017) - "These genes thus represent potential candidates that might be implicated in the disruption of normal stroma function, thus leading to disease development and progression. Accordingly, studies are underway to investigate the effects of selected genes on stroma-myeloma crosstalk (dys)function."

Biosimilar • Hematological Malignancies • Multiple Myeloma • Oncology

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - P1/2; N=268; Recruiting; Sponsor: Bristol-Myers Squibb; Trial primary completion date: Jul 2020 ➔ Nov 2020

Clinical • Combination therapy • PD(L)-1 Biomarker • Trial primary completion date

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab (clinicaltrials.gov) - P1/2; N=221; Recruiting; Sponsor: Bristol-Myers Squibb; Trial completion date: May 2020 ➔ Sep 2022; Trial primary completion date: Mar 2019 ➔ Jul 2020

Clinical • Combination therapy • Trial completion date • Trial primary completion date